Pervasis Therapeutics to Present Data from Phase 1 and 2 Clinical Trials of Vascugel at the American Society of Nephrology 41st Annual Meeting and Scientific Exposition

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 30, 2008 - Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active therapies and devices to treat serious illnesses, today announced that data from the company's Phase 1 and Phase 2 trials of Vascugel(R) V-HEALTH (Vascular intimal Hyperplasia: Extending Arterial and venous patency, Limiting vascular Trauma, and inhibiting Hyperplasia while re-establishing vascular health) will be presented at the American Society of Nephrology 41st Annual Meeting and Scientific Exposition during Renal Week 2008 in Philadelphia, Pennsylvania.

The poster presentation, entitled "Safety of Vascugel(R) Treatment after the Creation of Arteriovenous Access," will be presented by Prabir Roy-Chaudhury, M.D., associate professor of medicine, section chief of transplantation, Division of Nephrology, University of Cincinnati, on Thursday, November 6, 2008 at 10:00 a.m. (EST).

"We look forward to presenting safety data from our V-HEALTH trials at the American Society of Nephrology Meeting," stated Frederic Chereau, president and chief executive officer of Pervasis Therapeutics. "These data build on the promising Phase 1 study results and further demonstrate that all primary endpoints of the trial were met, with no significant safety issues. Vascular access failure is a major complication in providing care to patients who require a permanent arteriovenous access and we believe Vascugel(R) provides an unparalleled treatment solution."

About Vascugel(R)

Vascugel(R) is a novel and unique allogeneic cell therapy product under investigation for enhancing repair, extending patency and vascular health. Vascugel(R) builds on concepts of tissue engineering to enable implantation of allogeneic endothelial cells in a controlled state. When placed adjacent to an injured blood vessel, the endothelial cells in Vascugel(R) provide growth regulatory compounds to the underlying blood vessel, which promotes a natural healing process and may prevent excessive, inflammation, thrombosis and stenosis. Vascugel(R) has been studied in two Phase 2 clinical trials in patients with end stage renal disease.

About Pervasis Therapeutics, Inc.

Pervasis Therapeutics, Inc. is a clinical-stage regenerative therapeutics company developing biologically active products to address complex diseases and unmet medical needs. The Company has developed a proprietary allogeneic endothelial cell technology to regulate vascular repair and restore blood flow to critical vasculature and organs. Pervasis is also exploring broader indications in non-vascular applications, including inflammation, organ transplantation, nerve, wound and bone repair, and oncology. For more information, please visit www.pervasistx.com.

Contact

Pervasis Therapeutics, Inc.
Maggie Oâ??Toole, 617-871-1201
or
Pure Communications
Michele Rozen, 617-730-8284

Posted: October 2008

View comments

Hide
(web2)